<DOC>
	<DOCNO>NCT01965080</DOCNO>
	<brief_summary>A phase II study Exemestane Advanced recurrent endometrial carcinoma Hypothesis : Treatment With Exemestane give response rate least 30 %</brief_summary>
	<brief_title>Exemestane Advanced Recurrent Endometrial Carcinoma</brief_title>
	<detailed_description>Patients With Advanced recurrent endometrial cancer endometrioid type treat With Exemestane tablet 25 mg daily . Patients group accord estrogen receptor status .</detailed_description>
	<mesh_term>Endometrial Neoplasms</mesh_term>
	<mesh_term>Exemestane</mesh_term>
	<criteria>Advanced recurrent endometrial cancer consider treatment modality apart hormonal treatment Endometrioid histology Age 18 year Post menopausal status Performance status 02 Informed consent Congestive heart disease grade III.IV History thromboembolic sign Other primary hormonal therapy Patients With symptomatic brain metastasis Severe hepatic renal impairment Pregnancy , lactation child bear potential without adequate contraception</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>Endometrial cancer</keyword>
</DOC>